Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Eagle Pharmaceuticals Inc shares valued at $148,326 were sold by Tarriff Scott on Nov 02 ’23. At $13.87 per share, Tarriff Scott sold 10,694 shares. The insider’s holdings dropped to 545,447 shares worth approximately $2.86 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Tarriff Scott sold 10,925 shares, netting a total of over 150,984 in proceeds. Following the sale of shares at $13.82 each, the insider now holds 556,141 shares.
Before that, Tarriff Scott had sold 10,734 shares from its account. In a trade valued at $155,174, the CEO traded Eagle Pharmaceuticals Inc shares for $14.46 each. Upon closing the transaction, the insider’s holdings decreased to 10,734 shares, worth approximately $2.97 million.
As published in a research note from Piper Sandler on August 10, 2023, Eagle Pharmaceuticals Inc [EGRX] has been rated down from a Neutral to an Underweight and the price target has been revised to $17 from $26. Analysts at Piper Sandler downgraded the stock from ‘”a Neutral”‘ to ‘”an Underweight”‘ outlook in a report released in early August. Earlier on November 01, 2018, Cantor Fitzgerald downgraded its rating. Their new recommendation was “a Neutral” for EGRX stock which previously was a “an Overweight”.
Analyzing EGRX Stock Performance
During the last five days, there has been a surge of approximately 0.19%. Over the course of the year, Eagle Pharmaceuticals Inc shares have jumped approximately 0.19%. Shares of the company reached a 52-week high of $6.81 on 03/01/24 and a 52-week low of $4.10 on 01/16/24. A 50-day SMA is recorded $5.63, while a 200-day SMA reached $11.71. Nevertheless, trading volume fell to 80452.0 shares from 0.13 million shares the previous day.
Support And Resistance Levels for Eagle Pharmaceuticals Inc (EGRX)
According to the 24-hour chart, there is a support level at 5.01, which, if violated, would cause prices to drop to 4.78. In the upper region, resistance lies at 5.42. The next price resistance is at 5.60. RSI (Relative Strength Index) is 42.63 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.41, which suggests the price will decrease in the coming days. Percent R is at 73.85%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Eagle Pharmaceuticals Inc subject to short interest?
Stocks of Eagle Pharmaceuticals Inc saw a sharp rise in short interest on Mar 15, 2024 jumping by 100000.0 shares to 1.16 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 1.06 million shares. A jump of 8.62% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.17 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.17.
